Withanolide A extends the lifespan in human EGFR-driven cancerous Caenorhabditis elegans

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• The Epidermal Growth Factor Receptor (EGFR) pathway is implicated in various human cancers.
• Mutations in EGFR can lead to resistance against targeted therapies like gefitinib.
• Withania somnifera yields Withanolide A (WA), a compound known to influence aging and stress resistance via the Insulin/IGF-1 pathway.

Purpose of the Study:

• To investigate the effect of Withanolide A (WA) on the lifespan of C. elegans models with human EGFR-driven cancer.
• To assess WA's efficacy in EGFR models with specific mutations (L858R, T790M-L858R) associated with drug resistance.

Main Methods:

• Utilized C. elegans transgenic models engineered to express human EGFR.
• Examined the impact of WA on the lifespan of wild-type and mutant EGFR C. elegans strains.
• Monitored changes in fat levels in worms treated with WA.

Main Results:

• WA significantly extended the lifespan of EGFR-driven C. elegans models by 20.35% (wild-type), 24.21% (L858R mutation), and 21.27% (T790M-L858R double mutation).
• Reduced fat levels were observed in both wild-type N2 and transgenic C. elegans strains treated with WA.
• These findings suggest a healthspan-promoting effect, as high-fat diets are linked to tumor development.

Conclusions:

• Withanolide A demonstrates potential in extending lifespan across various human EGFR-driven C. elegans cancer models, including those with resistance mutations.
• WA's ability to reduce fat levels further supports its healthspan-promoting properties.
• Withanolide A shows promise as a nutraceutical for improving survival in cancer patients, particularly those with EGFR mutations resistant to current therapies.